Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
VOR BioPharma reports amended ownership disclosures by Qiming-related entities. The filing shows Qiming Venture Partners VIII-HC, L.P. beneficially owns 1,089,767 shares (2.0%), and Qiming Venture Partners VIII Investments, LLC beneficially owns 910,172 shares (1.7%). The filing cites 54,185,582 shares outstanding as of March 31, 2026 for percentage calculations.
The cover pages and incorporated items specify voting and dispositive power figures for each reporting person and include a joint filing agreement incorporated by reference.
VOR Biopharma Inc. amendment to a Schedule 13G/A reports that FMR LLC beneficially owns 1,539,670 shares of common stock, representing 3.2% of the class. The filing states FMR LLC has sole dispositive power over 1,539,670 shares and discloses related signature and exhibit references.
Vor Biopharma Inc. files a preliminary shelf prospectus to register for resale up to 5,338,078 shares of its common stock held by investors from a March 30, 2026 private placement. The shares were issued at $14.05 per share; Vor will receive no proceeds from resales. The registration satisfies contractual registration rights and the company agreed to use reasonable best efforts to have the registration declared effective.
Vor Biopharma Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026 at 9:00 a.m. Eastern Time. Holders of common stock at the April 15, 2026 record date may vote online or by proxy.
Stockholders will elect two Class II directors, Fouad Namouni and Andrew Levin, for terms running to the 2029 meeting, consider an amendment and restatement of the 2021 Equity Incentive Plan, and ratify Ernst & Young LLP as independent auditor for 2026. The amended plan keeps a 4% annual “evergreen” share increase but bases it on both common shares outstanding and shares issuable upon exercise of pre-funded warrants, and adds full vesting on death for time-based awards held by employees unless an award agreement provides otherwise.
Vor Biopharma Inc. reported an open‑market sale of its common stock by entities associated with RA Capital. On April 22, 2026, RA Capital Healthcare Fund LP sold 165,150 shares of Vor Biopharma common stock at a weighted average price of $15.77, through multiple trades between $15.75 and $15.85. After these transactions, the fund continued to hold 2,402,095 shares indirectly reported. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests.
RA Capital Management and affiliated funds report beneficial ownership of 12,896,519 shares of Vor Biopharma common stock, equal to 19.9% of the company. This stake is calculated against 54,185,582 shares outstanding as of March 30, 2026.
The position consists of 2,567,245 shares held directly by RA Capital Healthcare Fund and a mix of Common Stock Warrants for 1,056,072 shares and Pre-Funded Warrants for 10,000,000 shares, plus small option-related holdings. A “Beneficial Ownership Blocker” in the Pre-Funded Warrants limits exercise so the fund cannot exceed 19.99% ownership.
The fund reported recent open-market sales of 458,411 shares on April 17, 2026 at a weighted average price of $16.28 per share and 171,963 shares on April 20, 2026 at a weighted average price of $15.77 per share, as well as vesting of stock options with a $12.80 exercise price.
Vor Biopharma Inc. reported that an investment vehicle associated with RA Capital executed open-market sales of its Common Stock. On April 17, 2026, the RA Capital Healthcare Fund LP sold 458,411 shares at a weighted average price of $16.28 per share, in multiple trades between $15.95 and $16.85.
On April 20, 2026, the Fund sold an additional 171,963 shares at a weighted average price of $15.77 per share, with individual trades between $15.75 and $16.00. Following these transactions, the Fund held 2,567,245 shares of Vor Biopharma common stock indirectly, and RA Capital Management, its general partner and principals disclaim beneficial ownership beyond their pecuniary interests.
RA Capital Management and affiliated funds report beneficial ownership of 12,739,024 shares of Vor Biopharma common stock, representing 19.9% of the outstanding shares as of March 30, 2026. This percentage is based on 54,185,582 shares outstanding, adjusted for warrants and options exercisable within 60 days.
The position is held primarily through RA Capital Healthcare Fund, which owns 3,197,619 common shares, Common Stock Warrants for up to 1,056,072 shares, and Pre-Funded Warrants for up to 10,000,000 shares, plus small option positions held by Joshua Resnick and Andrew Levin for RA Capital’s benefit. Warrant “Beneficial Ownership Blockers” limit exercises above 9.99% for the Common Stock Warrants and above 19.99% for the Pre-Funded Warrants.
Recent activity includes open market sales by the Fund of 530,610 shares at a weighted average price of $16.15 on April 13, 2026, 153,735 shares at $15.97 on April 14, 2026, and 53,644 shares at $16.01 on April 15, 2026.